Skip to content
Molbio Diagnostics logo

Molbio Diagnostics

MOLBIO NSE
₹1,381.80 No trade today
P/E
123.38
View as Markdown
MCP
Close 4 Nov 2026 ₹1,381.80 +340.10 +32.6% since 17 Aug 2026
Start ₹1,041.70

Key Fundamentals

SmallcapMedical Equipment & SuppliesHealthcare

Price-based figures as of · TTM

ROCE
18.00%
Debt to Equity
0.31
EPS (TTM)
₹11.20
Book Value
₹118.84
Market Cap
—
P/E (TTM)
123.38
P/B
11.63
ROE
13.80%
Dividend Yield
0.00%
EBITDA
₹331 Cr
52W High
₹1,686.80
52W Low
₹926.35
Volume
0

Key Insights

Strengths

1
  • Company's working capital requirements have reduced from 179 days to 143 days

No weaknesses listed

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBullish2107
OscillatorsBearish261
Moving AveragesStrong Bullish046

Key readings

RSI (14)
53.97
Neutral
MACD (12,26,9)
0.23
Bearish
SMA (50)
1,306.31
Bullish
SMA (200)
—
Neutral

As of

Analyst Rating

Based on 1 analysts
BUY100%

1 of 1 analyst rates Buy, 0 Hold, 0 Sell.

As of

BUY
1
100%
HOLD
0
0%
SELL
0
0%

Growth Rate

From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025.

Revenue

Revenue growth by window
5Y+0.65%
3Y+58.94%
1Y+35.22%

Net profit

Net profit growth by window
5Y−18.77%
3Y+108.49%
1Y+3.57%

Operating cash flow

Operating cash flow growth by window
5YTurned negative
3YTurned negative
1YTurned negative

Operating margin· change in pp

Operating margin growth by window
5Y−27.62 pp
3Y+6.96 pp
1Y−4.08 pp

Trailing twelve months: Results are not reported for each of the last eight quarters, so there is no trailing-twelve-month figure.

Revenue by year

Revenue by year, ₹ crore
Mar 2021₹1,271 Cr
Mar 2022₹776 Cr
Mar 2023₹327 Cr
Mar 2024₹756 Cr
Mar 2025₹971 Cr
Mar 2026₹1,313 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2021₹410 Cr
Mar 2022₹187 Cr
Mar 2023₹16.00 Cr
Mar 2024₹111 Cr
Mar 2025₹140 Cr
Mar 2026₹145 Cr

Analyst Forecasts

Forecast For
FY27 consensus · EBITDA
₹478 Cr +44.6% vs FY26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 4 Nov 2026
AI opinion · based on fundamentals
Risk high

Molbio Diagnostics trades at a PE of 123.38x as of 2026-11-04, reflecting premium valuation for a healthcare diagnostics company with a market cap of ₹15,606.95 crore. The company has delivered strong 3-year compounded sales growth of 59% and profit growth of 111%, though longer-term 5-year trends show flat sales growth at 1% and negative profit growth of -19%, highlighting the cyclical nature of its earnings trajectory.

Bull Case 8
  • 3-year compounded profit growth of 111% demonstrates a strong earnings recovery cycle, significantly outpacing most diagnostics peers
  • 3-year compounded sales growth of 59% indicates robust revenue momentum and expanding market penetration
  • TTM sales growth of 35% shows the top-line acceleration is continuing into recent quarters
  • Low debt-to-equity ratio of 0.31 as of 2026-11-04 reflects a conservatively financed balance sheet with limited leverage risk
  • ROCE of 16.63% as of 2026-11-04 indicates the company is generating meaningful returns on total capital deployed
  • Working capital requirements have improved from 179 days to 143 days, freeing up cash and improving operational efficiency
  • The stock has rallied roughly 49% from its 52-week low of ₹926.35 to ₹1,381.80 as of 2026-11-04, reflecting improving investor sentiment
  • 3-year average ROE of 15% and 5-year average ROE of 16% suggest the company has maintained reasonable shareholder returns over multiple cycles
Bear Case 7
  • Price-to-book ratio of 11.63x as of 2026-11-04 implies the market is pricing in substantial future growth that may already be discounted
  • 5-year compounded profit growth of -19% reveals that current earnings remain below levels achieved five years ago, underscoring earnings volatility
  • 5-year compounded sales growth of just 1% indicates that the recent revenue surge may be a recovery rather than structural growth
  • TTM profit growth of only 1% suggests earnings expansion has stalled even as sales grew 35% in the same period, pointing to margin compression
  • Zero dividend yield as of 2026-11-04 means shareholders receive no income return and are entirely dependent on capital appreciation
  • Last year ROE of 14% trails the 5-year average of 16%, indicating a declining trend in return on equity
  • The stock trades about 18% below its 52-week high of ₹1,686.80, suggesting potential resistance at higher levels

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

9h ago

TL;DR: Molbio Diagnostics is delivering strong top-line growth with FY26 revenue up 41.7% and a dramatic Q1FY27 ramp, driven by rapidly scaling test-kit volumes on its proprietary Truenat platform. The recurring consumables model (74–75% of product revenue) and large untapped private-sector opportunity provide visible growth levers. Key risks include a stretched valuation at ~76–90x P/E, dependence on government tenders causing quarterly lumpiness, and still-modest capacity utilization. If the company executes on its FY27 margin and growth targets while expanding its private-sector and international footprint, the fundamental trend remains firmly positive despite near-term stock volatility.

Headwinds 4
  • High valuation, P/E near 90x Oct 22

    Stock trades at a P/E of roughly 76–90x at around ₹1,322–₹1,442 per share, with no meaningful historical valuation trend available given its recent listing.

  • Government tender dependence risk Oct 22

    Heavy reliance on government healthcare tenders and institutional procurement can cause lumpy, uneven quarterly results due to tender awards, approvals, and shipment schedules.

  • Stock fell ~7.9% in a day Oct 22

    Shares traded at ₹1,322 on Oct 21, down 7.86% from the previous close of ₹1,434.80.

Positives 7
  • FY26 revenue up 41.7% YoY Oct 22

    Revenue rose 41.7% YoY to ₹1,446 crore in FY26 while net profit increased 14.9% to ₹164 crore, with EBITDA margin improving to 22.6%.

  • Q1FY27 revenue surges 4x Oct 22

    Q1FY27 revenue jumped to ₹408.4 crore from ₹99.7 crore a year earlier, with EBITDA swinging to ₹103.7 crore from a loss of ₹14.5 crore in Q1FY26.

  • Test-kit volumes 41% CAGR Oct 22

    Test-kit volumes grew at a 41% CAGR from 8.8 million units in FY24 to 17.6 million in FY26, with Q1FY27 alone reaching 6.2 million units versus 0.8 million a year ago.

Neutral 1
  • Kotak MF crosses 5% stake Oct 13

    Kotak Mahindra Mutual Fund acquired 570,000 shares, taking its holding to 5.4834% under SAST regulations.

Quarterly Results

₹ Cr
MOLBIO quarterly results, ₹ crore
Particulars Jun 2025Mar 2026Jun 2026
Sales
95
439
399
Expenses
105
332
308
Operating Profit
−10
107
92
OPM %
−10%
24%
23%
Other Income
1
3
1
Interest
2
9
9
Depreciation
7
10
8
PBT
−17
91
76
Tax %
−23%
28%
25%
Net Profit
−13
66
57
EPS (₹)
−5.95
5.83
5.02

Profit & Loss

₹ Cr
MOLBIO profit and loss, annual, ₹ crore
Particulars Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
1,271
776
327
756
971
1,313
Expenses
676
457
286
552
746
1,061
Operating Profit
595
319
40
204
226
252
OPM %
47%
41%
12%
27%
23%
19%
Other Income
1
5
8
−21
−2
4
Interest
35
25
6
8
9
23
Depreciation
12
42
19
24
26
36
PBT
549
258
23
152
188
198
Tax %
25%
27%
32%
27%
26%
27%
Net Profit
410
187
16
111
140
145
EPS (₹)
2,027
833
69
493
62
12.83
Div. Payout %
0%
0%
0%
0%
0%
0%

Balance Sheet

₹ Cr
MOLBIO balance sheet, annual, ₹ crore
Particulars Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
2
2
2
2
2
11
Reserves
333
681
737
848
988
1,123
Borrowings
257
105
57
70
26
346
Other Liabilities
215
85
123
157
291
260
Total Liabilities
806
874
920
1,077
1,307
1,741
Fixed Assets
55
182
189
209
215
257
CWIP
100
0
0
2
18
6
Investments
9
9
54
54
95
317
Other Assets
643
683
676
813
980
1,160
Total Assets
806
874
920
1,077
1,307
1,741

Cash Flow

₹ Cr
MOLBIO cash flow, annual, ₹ crore
Particulars Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
344
98
68
38
249
−38
Investing
−142
−87
−51
−31
−98
−256
Financing
−192
−20
31
−24
−17
292
Net Cash Flow
10
−9
48
−18
133
−2
Free Cash Flow
212
35
55
24
206
−74
CFO/OP
78
53
251
39
139
6

Ratios

MOLBIO financial ratios, annual
Particulars Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
61
113
194
174
86
100
Inventory Days
261
402
885
393
395
286
Days Payable
124
64
201
129
226
130
Cash Conversion Cycle
198
450
877
438
254
256
Working Capital Days
75
206
479
239
155
143
ROCE %
—
41%
4%
22%
21%
18%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Molbio Diagnostics insights

33 extracted metrics across FY21–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 41.29%
  • Public 25.00%
  • DIIs 19.08%
  • Others 13.04%
  • FIIs 1.59%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

A trend needs at least two reported periods.

Documents

Frequently Asked Questions about Molbio Diagnostics

What does Molbio Diagnostics Ltd do?
Molbio Diagnostics is an innovative point- of-care (POC) diagnostics company that develops affordable, rapid, and accurate diagnostic solutions for infectious and non-communicable diseases.
Where is Molbio Diagnostics Ltd (MOLBIO) listed?
Molbio Diagnostics Ltd trades as MOLBIO on the NSE and under code 544866 on the BSE.
Which sector does Molbio Diagnostics Ltd belong to?
Molbio Diagnostics Ltd is classified under the Healthcare sector, in the Healthcare Equipment & Supplies industry.
What is the PE ratio of Molbio Diagnostics Ltd?
Molbio Diagnostics Ltd trades at a PE ratio of 123.38 as of 4 Nov 2026, on earnings per share of ₹11.2, against a book value of ₹118.84 per share.
What is the 52-week high and low of Molbio Diagnostics Ltd?
Over the last 52 weeks Molbio Diagnostics Ltd has traded between ₹926.35 and ₹1,686.8 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Molbio Diagnostics Ltd?
Molbio Diagnostics Ltd reported a return on equity of 13.80%. Its debt-to-equity ratio is 0.31.

Company Information

Molbio Diagnostics is an innovative point- of-care (POC) diagnostics company that develops affordable, rapid, and accurate diagnostic solutions for infectious and non-communicable diseases. Its flagship product, Truenat, is a portable, battery-powered PCR testing platform that delivers results within an hour. Designed for use in resource-limited settings, it enables quick and decentralised disease diagnosis at the point of care. Through its wholly owned subsidiary, Bigtec Labs, Molbio has strong research and development capabilities focused on creating diagnostic platforms for point-of- care (POC) testing. From product development to large-scale deployment, the company aims to improve access to reliable and affordable healthcare for everyone.

Website molbiodiagnostics.com
Listed 17 Aug 2026
Face Value ₹1

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/MOLBIO.md for Molbio Diagnostics Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month